Catalent is a global leader in providing integrated services, superior delivery technologies, and manufacturing solutions to help life science innovators develop and launch successful pharmaceuticals, biologics, and consumer health products.

Pharmaceutical

Catalent

Mr. Jenkins offers more than 28 years of leadership experience, and joined the company from GE Healthcare, where he worked for 18 years, holding positions including X-Ray Service Operations Director for the Americas, and Director of Service for the Connecticut and Atlanta regions. Prior to GE Healthcare, Mr. Jenkins worked at Fujitsu Network Communications and served for more than seven years in the United States Army. He earned a bachelor’s degree in economics from the United States Military Academy at West Point, New York.

Harold A. Jenkins III

Barry Littlejohns is the current President of Biologics & Specialty Drug Delivery at [Catalent](/org/catalent). Prior to this, they served as the Senior Vice President of Operations at [Genmab](/org/genmab) from July 2009 to July 2010. [Genmab](/org/genmab) is a Danish company dedicated to creating and developing human antibodies, with a focus on Oncology. Barry was responsible for global operations at [Genmab](/org/genmab), overseeing manufacturing, CMC, quality, and preclinical and clinical operations. 

From January 2009 to July 2009, Barry Littlejohns served as the Vice President of Global Business Operations at [Catalent](/org/catalent) Pharma Solutions. [Catalent](/org/catalent) Pharma Solutions is a leading provider of manufacturing and packaging services for the pharmaceutical industry with 30 facilities in 12 countries and 9,400 employees. In this role, Barry was responsible for managing all indirect and SG&A expenses through an Indirect Bullet Train Program. Barry developed and implemented systems, processes and initiatives that generated cash savings of $25 million in the first year. Barry also established a framework of 35 Indirect Leaders throughout the organization and set up systems and processes to manage projects in all countries and functions.

Barry Littlejohns has a degree in finance from the University of Derby and an HND in business and finance from Swindon College.

They are on a team with Tom Castellano - SVP, CFO, Karen Santiago - VP & Chief Accounting Officer, and Charles Lickfold - SVP & CIO. Barry Littlejohns reports to Alessandro Maselli, President, CEO & Board Member.

Barry Littlejohns

Karen Flynn has been a board member since September 2022. Ms. Flynn retired in July 2022 from her position as Catalent’s Senior Vice President & Chief Commercial Officer, a position she had held since 2021. She joined Catalent as President, Biologics and Chief Commercial Officer in 2020. Prior to joining Catalent, she served as the Senior Vice President and Chief Commercial Officer of West Pharmaceutical Services, Inc. from 2016 to 2019, having previously served as that company’s President, Pharmaceutical Packaging Systems since 2014. Ms. Flynn is also a director of Quanterix Corporation and serves in the Hesburgh Women of Impact mentorship program for the University of Notre Dame. She has previously served on the Chester County Economic Development Council Board of Directors, the Downingtown STEM Academy Advisory Board, and on the Board of Directors for Recro Pharmaceuticals. 

Ms. Flynn holds a Master of Science in Business Administration from Boston University, a Master of Science in Engineering from the University of Pennsylvania, and a Bachelor of Science in Pre-Professional Studies (Pre-Med) from the University of Notre Dame.



Karen Flynn

Ricardo Pravda was named Senior Vice President and Chief Human Resources Officer in July 2019. Since joining [Catalent](/org/catalent) as HR Director for Latin America in 2005, Mr. Pravda held several leadership roles supporting multiple businesses and locations, most recently as VP of Human Resources for [Catalent](/org/catalent)’s network of sites globally.

Mr. Pravda has over 25 years of experience in many HR disciplines including compensation, succession planning, organizational design, performance management, labor relations, acquisitions, and divestitures. He has supported businesses in the Americas, Europe, and Asia-Pacific, holding roles of increasing responsibility in companies like Nabisco, Phillip Morris International, BellSouth International, and The Gillette Company.

Ricardo Pravda

Karen Santiago was named Vice President & Chief Accounting Officer in September 2022. Prior to joining Catalent, she spent 19 years with Bristol-Myers Squibb Company in various roles of increasing responsibility, including Senior Vice President & Corporate Controller, Principal Accounting Officer from 2018 to 2022 and Lead Enabling Functions and Finance Transformation from 2016 to 2018. Since 2013 Ms. Santiago has served on the board of The Arc of New Jersey, the state’s largest organization advocating for and serving children and adults with intellectual and developmental disabilities and their families. She holds a Masters in Business Administration and a Bachelor of Science in Accounting from Rutgers University.



Karen Santiago

Michael J. Barber has been a board member since April 2021. He currently serves as the Chief Diversity Officer for General Electric Company. During his forty-year career at GE, Mr. Barber has had a variety of progressively senior roles in engineering, operations, and product management, including service as President and CEO of GE Molecular Imaging and Computed Tomography from 2016 until 2020; as Chief Engineer, [GE Healthcare](/org/ge-healthcare-limited) and Chief Operating Officer, [GE Healthcare](/org/ge-healthcare-limited) Systems from 2013 until 2015; as VP and General Manager, Molecular Imaging, [GE Healthcare](/org/ge-healthcare-limited) in 2012; as Vice President, healthymagination (GE Corporate) from 2009 until 2011; and as Vice President and CTO, [GE Healthcare](/org/ge-healthcare-limited) from 2007 until 2008. Among other prestigious awards, he was named a “Master of Innovation” by Black Enterprise in 2009 and elected a Fellow of the American Institute of Medical and Biological Engineering in 2014. He has served as a director of Talix, Inc. since 2017, and served as a director of Healthline, Inc. from 2009 until its acquisition by [Summit Partners](/org/summit-partners) in 2016. He is also a board member of the National Action Council for Minorities in Engineering (NACME).

Mr. Barber received a B.S. in electrical engineering and an honorary doctorate in engineering from the [Milwaukee School of Engineering](/org/milwaukee-school-of-engineering), where he also serves as a Regent.

Michael J. Barber

Jonathan Arnold was named Senior Vice President, Chief Commercial Officer, and Head of Transformation in July 2022.Prior to that, he served since October 2017 as President of our Oral & Specialty Delivery business and, earlier, for six years as Vice President and General Manager of the company’s Drug Delivery Solutions business unit.

Mr. Arnold’s career in the life sciences CDMO (contract development and manufacturing organization) sector began in 1995, when he joined R.P. Scherer, a leader in softgel technologies and forerunner to [Catalent](/org/catalent), where he served in a variety of international business development and strategic customer account roles over the course of 5 years. He spent 11 years working for Patheon, another contract development and manufacturing organization, in multiple locations, including Italy, the U.K., and Switzerland, serving in roles of increasing responsibility, including Vice President of Global Supply Chain and, ultimately, Chief Procurement Officer, before returning to [Catalent](/org/catalent) in 2011. Prior to working in the life sciences sector, Mr. Arnold had an international business development and strategic marketing role for the U.K.’s largest waste management company, Shanks & McEwan. Mr. Arnold earned his bachelor’s degree in Agriculture, Biochemistry, and Nutrition from the [University of Newcastle](/org/university-of-newcastle) upon Tyne, U.K.

Jonathan Arnold

Dr. Donald E. Morel has been a board member since November 2015. Dr. Morel retired in June 2015 as Chairman of West Pharmaceutical Services, Inc., a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products, a position he had held since March 2003. He also served as West’s Chief Executive Officer from April 2002 until April 2015 and as its President from April 2002 until June 2005.



Donald E. Morel

Kay Schmidt was named Senior Vice President, Enterprise Functions in July 2022. Prior to that, she served as Senior Vice President, Enterprise Functions and Chief of Staff since October 2021 and, earlier, as Senior Vice President, Technical Operations since February 2019. Ms. Schmidt joined [Catalent](/org/catalent) in 2009, holding several leadership roles in product development across multiple drug delivery dosage forms, including her leadership of our global virtual Project Management Organization for new product introductions, in addition to her role as Vice President, Product Development in our Biologics and Specialty Drug Delivery business. Prior to joining [Catalent](/org/catalent), she held various leadership roles at [GE Healthcare](/org/ge-healthcare-limited) developing and delivering diagnostic imaging technologies. She is a certified Six Sigma Green Belt, and has a bachelor’s degree from Carroll University, Wisconsin and a master’s degree from the University of Wisconsin-Whitewater.



Kay Schmidt

John Greisch has been a board member since February 2018. Mr. Greisch retired in May 2018 from his position as President and Chief Executive Officer of Hill-Rom Holdings, Inc., a position that he had held since 2010. Prior to that, Mr. Greisch was President International Operations for Baxter International, Inc., a position he held beginning in 2006. During his seven-year tenure with Baxter, he also served as Baxter’s Chief Financial Officer and as President of Baxter’s BioScience division. Before his time with Baxter, Mr. Greisch was President and Chief Executive Officer for [FleetPride](/org/fleetpride-inc) Corporation in Deerfield, Illinois, an independent after-market distribution company serving the transportation industry. Prior to his tenure at [FleetPride](/org/fleetpride-inc), he held various positions at The Interlake Corporation, including serving as President of its Materials Handling Group.



John Greisch

Rolf Classon has been a board member since August 2014. From October 2002 until his retirement in July 2004, Mr. Classon was Chairman of the Executive Committee of Bayer HealthCare AG, a subsidiary of Bayer AG. He served as President of Bayer Diagnostics from 1995 to 2002 and as Executive Vice President of Bayer Diagnostics from 1991 to 1995. Prior to 1991, Mr. Classon held various management positions with Pharmacia Corporation. Mr. Classon currently serves as Chairman of the Board of Directors of Perrigo Company plc and as a member of the Supervisory Board of [Fresenius Medical Care](/org/fresenius-medical-care). He was previously Chairman of the Board of Directors of Tecan Group Ltd., serving from 2009 until April 2018. Mr. Classon served as Chairman of the Board of Directors of Hill-Rom Corporation from 2006 until March 2018, also serving as Vice Chairman of the Board from 2003 through May 2005 and as interim chief executive officer from May 2005 until March 2006. From 2005 to 2015, Mr. Classon served as Chairman of the Board of Directors of Auxilium Pharmaceuticals, Inc., and as Vice Chairman from March 2005 to April 2005. He also previously served as a director of Sequanna Medical AG from 2016 to 2017; of Aerocrine AB, Stockholm from 2013 to 2015; of Millipore Corporation from 2005 to 2010; of Prometheus Laboratories Inc. from 2004 to 2010; and of Enzon Pharmaceuticals Inc. from 1997 to 2011.


Rolf Classon

Steven Fasman was named Executive Vice President and Chief Administrative Officer in July 2022.  Prior to that, he served as Senior Vice President and General Counsel since October 2014. Before joining [Catalent](/org/catalent), he served as Executive Vice President-Law of MacAndrews & Forbes Holdings Inc., a privately held diversified holding company, from January 2012 to March 2014. Before that, Mr. Fasman held various positions at MacAndrews & Forbes Holdings since 1992 of increasing responsibility.

From 2008 through March 2014, he also served as General Counsel and Chief Compliance Officer of M & F Worldwide Corp., which had interests in financial products, customer calling centers, staffing operations, educational software, and flavoring products. From 2008 to 2011, Mr. Fasman also served as a director of SIGA Technologies, Inc., a biodefense company.

Mr. Fasman spent his early career at the law firm of Paul, Weiss, Rifkind, Wharton & Garrison, where he focused on domestic and international litigation and regulatory proceedings. He holds a law degree from [Yale University](/org/yale-university) and an A.B. degree in mathematics from [Princeton University](/org/princeton).



Steven Fasman

Trish Hunt was named President, Division Head for Consumer Health in July 2022. Prior to that, she served as Global Vice President of Business Development for our Softgel & Oral Technologies business since February 2022 and, earlier, as Vice President, Global Nutritionals & Beauty since September 2019 and Vice President & General Manager of Global Cosmetics since July 2016. Earlier in her Catalent career, she held various leadership positions within our supply chain function and developed the “I am Catalent” customer service excellence training program. Prior to joining Catalent, Ms. Hunt worked in a variety of industries, including banking and entertainment. Ms. Hunt has a bachelor’s degree from Niagara University and a Master’s of Science degree in Organizational Leadership from Pfeiffer University.



Trish Hunt

Tom Hawkeswood was named President, Division Head of Pharma Product Delivery in July 2022. Prior to that, he served as Vice President, Operations for our former Softgel & Oral Technologies business with respect to geographic regions of increasing scope since February 2019. He joined Catalent as Vice President and General Manager of our Canadian softgel sites in February 2017 when we acquired Accucaps Industries Limited, where he had worked for the prior 10 years in positions of increasing responsibility. Earlier in his career, he worked for 6 years at a subsidiary of ThyssenKrupp. Mr. Hawkeswood has a bachelor’s degree in mechanical engineering from Queen’s University and an MBA from the University of Windsor, both located in Ontario, Canada.



Tom Hawkeswood

Ricky Hopson was named President, Division Head for Clinical Development & Supply in July 2022. Prior to that, he served as Vice President & Chief Accounting Officer since June 2021. Mr. Hopson has been with Catalent for more than 20 years, serving in a variety of finance roles, including Vice President & Corporate Controller, Global Vice President, Operational Finance, and Vice President of Finance for two different business units. Mr. Hopson graduated from the University of Portsmouth and is a chartered management accountant in the U.K.



Ricky Hopson

Mike Riley was named President, Division Head for Bio Product Delivery in July 2022. Prior to that, he served since October 2021 as President of our Biotherapeutics business and, earlier, as the Regional President for North America and as Vice President/General Manager of Catalent Biologics for five years. Mr. Riley has over 15 years of experience at Catalent, previously serving as Vice President of Strategy, Advanced Delivery Technologies, and Vice President, Global Business Development for Catalent Sterile Technologies. Prior to joining Catalent, Mike worked as a management consultant for Marakon Associates, providing strategic advisory to companies across multiple industries. Mike holds a B.A. from Duke University, and an MBA from The Wharton School, University of Pennsylvania.



Mike Riley

Dr. Manja Boerman was named President, Division Head for BioModalities in July 2022. Prior to that, she served since June 2020 as President of our Cell & Gene Therapy business. Dr. Boerman joined Catalent in December 2019 as Region President, Biologics Europe. Before joining Catalent, Dr. Boerman served as President of Aesica Pharmaceuticals, a U.K.-based CDMO, and earlier as CEO of Opnostics, Executive Director of Charles River Laboratories, and President of Patheon Biologics, among other roles. She holds a Ph.D. in Biochemistry from the State University of New York—Buffalo.



Manja Boerman

Charles Lickfold was named Senior Vice President and Chief Information Officer in May 2020. Prior to joining Catalent, Mr. Lickfold held numerous IT leadership positions, including CIO for Alcami Corp., Avara Pharmaceutical Services, and Gilbarco-Veeder-Root. He also served as Vice President and Head of IT for Patheon and began his career as a management consultant in the life sciences practice of Ernst & Young LLP. He earned a bachelor’s degree in computer science from the University of Kentucky’s College of Engineering.



Charles Lickfold

Lorenzo Carletti was named Senior Vice President Global Operations, Pharma and Consumer Health in October 2021.  Mr. Carletti joined [Catalent](/org/catalent) in July 2013 as General Manager of the Aprilia site and was then promoted to Vice President, Operations in October 2016 with additional responsibilities added over time for sites in Europe, North and South America, Asia, and Australia. He also acted for a period as Interim Head of Technical Operations.

Prior to joining [Catalent](/org/catalent), he had roles of increasing responsibility in manufacturing, operational excellence, engineering, procurement, and supply chain with [Procter & Gamble](/org/procter-gamble), [Pfizer](/org/pfizer), Haupt Pharma (now part of Aenova Group), and Dompé.

Mr. Carletti received a degree in Engineering from the University of Rome “La Sapienza” in 1997 and a Master’s of Business Administration from the Open University Business School in 2013. He is also a certified APICS professional.

Lorenzo Carletti

John Chiminski was appointed [Catalent](/org/catalent)’s Executive Chair in July 2022. Prior to that he had served as [Catalent](/org/catalent)’s Chief Executive Officer since 2009. He joined [Catalent](/org/catalent) after more than 20 years of experience at [GE Healthcare](/org/ge-healthcare-limited) in engineering, operations, and senior leadership roles. From 2007 to 2009, Mr. Chiminski was President and Chief Executive Officer of GE Medical Diagnostics, a global business with sales of $1.9 billion. From 2005 to 2007, he served as Vice President and General Manager of [GE Healthcare](/org/ge-healthcare-limited)’s Global Magnetic Resonance Business, and from 2001 to 2005, as Vice President and General Manager of Global Healthcare Services. Earlier at GE, he held a series of cross-functional leadership positions in both manufacturing and engineering, including a GE Medical Systems assignment in France. Mr. Chiminski has served as a director of [Berkeley Lights](/org/berkeley-lights) since May 2021.

Mr. Chiminski holds a BS from [Michigan State University](/org/michigan-state-university) and an M.S. from [Purdue University](/org/purdue-university), both in electrical engineering, as well as a Master’s Degree in Management from the Kellogg School of Management at [Northwestern University](/org/northwestern-university).

John Chiminski

Mario Gargiulo

Tom Castellano was named Senior Vice President & Chief Financial Officer in June 2021. Mr. Castellano previously served as [Catalent](/org/catalent)’s Global Vice President of Operational Finance, providing finance partnership on strategic execution across the company’s business units, and as a member of [Catalent](/org/catalent)’s Executive Leadership Team. He joined the company as Director for Financial Planning & Analysis in 2008, playing an integral role in [Catalent](/org/catalent)’s successful initial public offering in 2014, and has served in successively senior positions since then, including as Vice President, Financial Planning & Analysis and Vice President, Finance, Investor Relations, and Treasurer. Prior to joining the company, he worked with the capital markets finance group at Lehman Brothers, holding roles of increasing responsibility. Tom began his career at Cendant Corporation as part of its financial leadership development program. He holds a bachelor’s degree in finance and an MBA, both from [Seton Hall University](/org/seton-hall-university).

Tom Castellano

Mike Grippo was named Senior Vice President, Strategy & Corporate Development in October 2019. He joined [Catalent](/org/catalent) in April 2016 as [Catalent](/org/catalent)’s Vice President of Corporate Development where he was charged with executing value-driving deals and developing a disciplined, inorganic growth strategy for the company.

Prior to joining [Catalent](/org/catalent), Mike was co-leader of corporate development for medical device company CR Bard, and held similar roles of leadership with Hill-Rom Holdings, Inc., a publicly traded medical technology company, and Welch Allyn, Inc., a privately held medical products company. Mike also previously worked as an investment banker for 12 years, primarily with SG Cowen and UBS Securities and Dillon Read.

Mike Grippo

Scott Gunther was named Senior Vice President of Quality & Regulatory Affairs in May 2017. Mr. Gunther joined Catalent in 2012 as Vice President, Quality and most recently has been overseeing the quality function for the United States sites in our Drug Delivery Solutions business unit. He previously also concurrently served as an interim Vice President of Product Development for the DDS business unit.


Scott Gunther

Aris Gennadios

Alessandro Maselli was appointed [Catalent](/org/catalent)’s President and Chief Executive Officer and joined the Board of Directors in July 2022. He previously served as the company’s President & Chief Operating Officer since February 2019. Mr. Maselli joined [Catalent](/org/catalent) in 2010 as Director of Operations at [Catalent](/org/catalent)’s pharmaceutical, nutritional and cosmetics plant in Aprilia, Italy. In 2013, he was appointed General Manager of Zydis® operations at [Catalent](/org/catalent)’s facility in Swindon, U.K, in 2015 he became Vice President of Operations, Europe, for [Catalent](/org/catalent)’s Drug Delivery Solutions business unit, and in 2016 he was named [Catalent](/org/catalent)’s Senior Vice President, Global Operations.

Prior to [Catalent](/org/catalent), Mr. Maselli held operational and business leadership roles at [Alstom](/org/alstom-sa) and SGS. From 1998 to 2006, he held roles of increasing responsibility from process engineer to operations director at ABB. Mr. Maselli began his career as an automation systems engineer in the food industry.

A native of Italy, Mr. Maselli earned bachelor and master degrees in electronic engineering from the University of Rome.

Alessandro Maselli

Madhavan Madhu Balachandran

J. Martin Carroll

Gregory T. Lucier

Peter Zippelius has been a board member since May 2019. Mr. Zippelius is a partner of Leonard Green & Partners, L.P., which he joined in 2018. Previously, he was a Managing Director and Co-Head of North American Healthcare Investment Banking at J.P. Morgan, which he joined in 2015. Prior to J.P. Morgan, Mr. Zippelius was a Managing Director and Co-Head of Healthcare Services Investment Banking at Deutsche Bank Securities and prior to that he was a Managing Director in the Healthcare Investment Banking group at Morgan Stanley. Mr. Zippelius began his career in the Mergers and Acquisitions department of Solomon Smith Barney. He earned a Bachelor of Science degree in Finance from [Virginia Tech](/org/virginia-tech).


Peter Zippelius

Dr. Christa Kreuzburg has been a board member since February 2018. Dr. Kreuzburg has been consulting in the healthcare sector since retiring from Bayer AG in 2009 after 19 years of service in a variety of roles, including service as Head of the Bayer Schering Pharma Europe/Canada unit of Bayer Healthcare from 2007 to 2008 and as Head of the Pharma Primary Care/International Operations unit of Bayer Healthcare from 2006 to 2007. She also held roles in the Strategic Planning and Central Research groups. Dr. Kreuzburg is currently a member of the board of directors of Tecan Trading AG of Switzerland and has previously served as a director of Freedom Innovations LLC.


Christa Kreuzburg

Rosemary Crane has been a board member since February 2018. Ms. Crane is currently a member of the board of directors of Teva Pharmaceutical Industries Limited, where she serves as chair of the board’s Human Resources Compensation Committee, and has previously served as a director of Edge Therapeutics, Inc., Unilife Corporation, Cipher Pharmaceuticals, MELA Sciences, Inc., Epocrates Inc., Targanta Therapeutics, and Zealand Pharma A/S. She also serves as a director of Hackensack Meridian Health Center for Discovery and Innovation. Ms. Crane retired in 2014 from MELA Sciences, Inc., where she served as President and Chief Executive Officer beginning in 2013. From 2011 to 2013, she was a Partner and Head of Commercialization at Appletree Partners and, from 2008 to 2011, served as Chief Executive Officer and President of Epocrates Inc. From 2002 to 2008, Ms. Crane served in several senior executive positions at the Johnson & Johnson Group of Companies, ending as Company Group Chairman, OTC and Nutritional Group. From 1982 to 2002, she was at Bristol-Myers Squibb Company, ending her tenure there as President, U.S. Primary Care.


Rosemary Crane

Jack Stahl has been a board member since August 2014. Mr. Stahl was the President and Chief Executive Officer of [Revlon](/org/revlon) Inc. from 2002 until his retirement in 2006. Prior to joining [Revlon](/org/revlon), Mr. Stahl served as President and Chief Operating Officer of [The Coca-Cola Company](/org/the-coca-cola-company) from 2000 to 2001, having previously served in various management positions at that company since joining it in 1979. Mr. Stahl serves on the boards of United Natural Food, Inc. and Advantage Solutions LLC and on the U.S. board of advisors of CVC Capital. Additionally, he formerly served on the boards of Schering-Plough Corporation, Dr Pepper Snapple Group, Saks, Inc., Coty Inc., and [Ahold Delhaize](/org/ahold-delhaize), and was chairman of the board of managers of New Avon LLC.


Catalent

Org chart

Teams

Leadership Team

Board of Directors

CEO and Executive Team

Discover similar companies